FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012253802> ?p ?o ?g. }

• W2012253802 endingPage "20" @default.
• W2012253802 startingPage "9" @default.
• W2012253802 abstract "Immune thrombocytopenia (ITP) is an autoimmune disorder characterised by abnormally low platelet counts (<100 x 10(9)/l), purpura, and bleeding episodes, and can be categorised in three phases: newly-diagnosed, persistent, and chronic. As many patients become refractory to standard treatments (corticosteroids, danazol, azathioprine, splenectomy), there is an urgent need for alternative treatments. The successful isolation and cloning of thrombopoietin (TPO) in the mid-1990s and identification of its key role in platelet production was a major breakthrough, rapidly followed by the development of the recombinant thrombopoietins, recombinant human TPO and a pegylated truncated product, PEG-rHuMGDF. Both agents increased platelet counts but development was halted because of the development of antibodies that cross-reacted with native TPO, resulting in prolonged treatment-refractory thrombocytopenia. Experimentation with novel platforms for extending the circulating half-life of therapeutic peptides by combining them with antibody fragment crystallisable (Fc) constructs led to the development of a new family of molecules termed 'peptibodies'. The 60Da recombinant peptibody romiplostim was finally produced by linking several copies of an active TPO-binding peptide sequence to a carrier Fc fragment. In clinical trials, romiplostim was effective in ameliorating thrombocytopenia in patients with chronic ITP, was well tolerated and did not elicit cross-reacting antibodies. Romiplostim has recently been approved for the treatment of adults with chronic ITP." @default.
• W2012253802 created "2016-06-24" @default.
• W2012253802 creator A5004893650 @default.
• W2012253802 creator A5011059993 @default.
• W2012253802 date "2010-06-09" @default.
• W2012253802 modified "2023-10-17" @default.
• W2012253802 title "Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia: from bench to bedside" @default.
• W2012253802 cites W125588914 @default.
• W2012253802 cites W131887615 @default.
• W2012253802 cites W1512739303 @default.
• W2012253802 cites W1857855102 @default.
• W2012253802 cites W1861179146 @default.
• W2012253802 cites W189385581 @default.
• W2012253802 cites W1903176849 @default.
• W2012253802 cites W1965375035 @default.
• W2012253802 cites W1967383618 @default.
• W2012253802 cites W1968086694 @default.
• W2012253802 cites W1971957984 @default.
• W2012253802 cites W1974541132 @default.
• W2012253802 cites W1979820418 @default.
• W2012253802 cites W1980002878 @default.
• W2012253802 cites W1983460692 @default.
• W2012253802 cites W1983612778 @default.
• W2012253802 cites W1983765869 @default.
• W2012253802 cites W198401084 @default.
• W2012253802 cites W1984073642 @default.
• W2012253802 cites W1984302960 @default.
• W2012253802 cites W1989118573 @default.
• W2012253802 cites W1993960588 @default.
• W2012253802 cites W1994397765 @default.
• W2012253802 cites W1996093792 @default.
• W2012253802 cites W1997632886 @default.
• W2012253802 cites W1999329955 @default.
• W2012253802 cites W2003550375 @default.
• W2012253802 cites W2006379085 @default.
• W2012253802 cites W2010196417 @default.
• W2012253802 cites W2011722739 @default.
• W2012253802 cites W2013946336 @default.
• W2012253802 cites W2014207233 @default.
• W2012253802 cites W2020917228 @default.
• W2012253802 cites W2025122282 @default.
• W2012253802 cites W2032559502 @default.
• W2012253802 cites W2032660521 @default.
• W2012253802 cites W2038751394 @default.
• W2012253802 cites W2038818733 @default.
• W2012253802 cites W2039211544 @default.
• W2012253802 cites W2040530937 @default.
• W2012253802 cites W2043704659 @default.
• W2012253802 cites W2047289361 @default.
• W2012253802 cites W2047557050 @default.
• W2012253802 cites W2059190713 @default.
• W2012253802 cites W2062525245 @default.
• W2012253802 cites W2073189639 @default.
• W2012253802 cites W2081185151 @default.
• W2012253802 cites W2087844863 @default.
• W2012253802 cites W2088340306 @default.
• W2012253802 cites W2093758335 @default.
• W2012253802 cites W2094920967 @default.
• W2012253802 cites W2100408134 @default.
• W2012253802 cites W2103818290 @default.
• W2012253802 cites W2105183923 @default.
• W2012253802 cites W2110956170 @default.
• W2012253802 cites W2115876636 @default.
• W2012253802 cites W2119920607 @default.
• W2012253802 cites W2121116928 @default.
• W2012253802 cites W2127498947 @default.
• W2012253802 cites W2136971471 @default.
• W2012253802 cites W2139745353 @default.
• W2012253802 cites W2142812740 @default.
• W2012253802 cites W2143531841 @default.
• W2012253802 cites W2145139769 @default.
• W2012253802 cites W2145439228 @default.
• W2012253802 cites W2147558891 @default.
• W2012253802 cites W2152700768 @default.
• W2012253802 cites W2153674764 @default.
• W2012253802 cites W2166734831 @default.
• W2012253802 cites W2167810526 @default.
• W2012253802 cites W2174762922 @default.
• W2012253802 cites W2230842386 @default.
• W2012253802 cites W2242685879 @default.
• W2012253802 cites W2258879728 @default.
• W2012253802 cites W2260183312 @default.
• W2012253802 cites W2263191133 @default.
• W2012253802 cites W2272820281 @default.
• W2012253802 cites W2279148850 @default.
• W2012253802 cites W2288265765 @default.
• W2012253802 cites W2330913380 @default.
• W2012253802 cites W2801927229 @default.
• W2012253802 cites W350217275 @default.
• W2012253802 cites W4232025330 @default.
• W2012253802 cites W4250757791 @default.
• W2012253802 cites W92133935 @default.
• W2012253802 doi "https://doi.org/10.1111/j.1365-2141.2010.08140.x" @default.
• W2012253802 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20298251" @default.
• W2012253802 hasPublicationYear "2010" @default.
• W2012253802 type Work @default.
• W2012253802 sameAs 2012253802 @default.
• W2012253802 citedByCount "37" @default.

• next